

Lifeline Drugs & Pharma Limited
Registered Office : A-401, 4th Floor, Mastermind III, Royal Palms Estate, Aarey Milk Colony
Goregaon (E), Mumbai-400 065

Statement of Unaudited Results for the Quarter & 12 months ended 31st March 2012

Rs. in Lacs

Sr. No.	Particulars	3 Months ended	Preceding 3	Corresponding 3	Year to date	Year to date
		31.03.12	Months ended	Months ended	figures as on	figures as on
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income from Operations					
	a) Net Sales/Income from Operations	-	-	(0.03)	-	1,625.98
	b) Other Operating Income	-	-	-	-	-
	Total Income from Operations (Net)	-	-	(0.03)	-	1,625.98
2	Expenses					
	(a) Cost of Material Consumed	-	-	(0.02)	-	99.88
	(b) Purchases of Stock-in-trade	-	-	0.03	-	1,516.93
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(d) Employees Benefit Expenses	0.54	0.52	0.05	2.02	4.65
	(e) Depreciation & Amortization Expenses	-	-	-	-	-
	(f) Other Expenses	1.78	1.64	0.08	6.35	4.78
	Total Expenses	2.32	2.16	0.14	8.37	1,626.24
3	Profit/(Loss) from Operations before other income, finance cost and exceptional Expenses (1-2)	(2.32)	(2.16)	(0.17)	(8.37)	(0.27)
4	Other Income/(Loss)	3.88	3.02	-	13.46	-
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	1.56	0.86	(0.17)	5.09	(0.27)
6	Finance Costs	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3-4)	1.56	0.86	(0.17)	5.09	(0.27)
8	Exceptional Items	-	-	-	-	-
9	Profit(+)/Loss(-) from ordinary activities before Tax (7-8)	1.56	0.86	(0.17)	5.09	(0.27)
10	Tax Expense	-	-	-	-	-
11	Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)	1.56	0.86	(0.17)	5.09	(0.27)
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11-12)	1.56	0.86	(0.17)	5.09	(0.27)
14	Share of Profit/(Loss) of Associates*	-	-	-	-	-
15	Minority Interest*	-	-	-	-	-
16	Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)	1.56	0.86	(0.17)	5.09	(0.27)
17	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	24.00	24.00	24.00	24.00	24.00
18	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	-	-
19	Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not annualized)					
	(i) a) Basic	0.65	0.36	(0.07)	2.12	(0.11)
	b) Diluted	0.65	0.36	(0.07)	2.12	(0.11)
19	Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not annualized)					
	(ii) a) Basic	0.65	0.36	(0.07)	2.12	(0.11)
	b) Diluted	0.65	0.36	(0.07)	2.12	(0.11)
A	PARTICULARS OF SHAREHOLDING					
	Public Shareholding					
	- Number of Shares	138,790	138,790	138,790	138,790	138,790
	- Percentage of Share Holding	57.83	57.83	57.83	57.83	57.83
18	Promoter and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-
	b) None-Encumbered					
	- Number of Shares	101,210	101,210	101,210	101,210	101,210
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	42.17	42.17	42.17	42.17	42.17
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the Quarter	-	-	-	-	-
	Received during the Quarter	-	-	-	-	-
	Disposed during the Quarter	-	-	-	-	-
	Remaining Unresolved at the end of Quarter	-	-	-	-	-

Notes :

- Segmental Report for the Quarter as per AS-17 is not applicable for the current Quarter.
- Above results were reviewed by Audit Committee taken on record in Board Meeting held on 14th May 2012.
- Statutory Auditors of the Company have carried Limited Review for above Results.



For Lifeline Drugs & Pharma Limited

Place : Mumbai
Date : 14th May 2012S/d-
Director

Lifeline Drugs & Pharma Limited
Statement of Assets & Liabilities

Rs. in Lacs

Particulars	For the Year Ended	
	31/03/2012	31/03/2011
	Un-Audited	Audited
A EQUITY & LIABILITIES		
1 Shareholders' Fund		
(a) Share Capital	24.00	24.00
(b) Reserves and Surplus	115.05	109.96
(c) Money Received against Share Warrants	-	-
Sub-Total - Share Holders Fund	139.05	133.96
2 Share Capital Money (Pending Allotment)	-	-
3 Minority Interest*	-	-
4 Non Current Liabilities		
(a) Long Term Borrowings	-	-
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	-	-
Sub-Total - Long Term Liabilities	-	-
5 Current Liabilities		
(a) Short Term Borrowings	-	-
(b) Trade Payables	0.30	0.30
(c) Other Current Liabilities	17.78	17.78
(d) Short Term Provisions	2.81	2.81
Sub-Total - Current Liabilities	20.89	20.89
TOTAL EQUITY & LIABILITIES	159.94	154.85
B ASSETS		
1 Non-Current Assets		
(a) Fixed Assets	-	-
(b) Goodwill on Consolidation*	-	-
(c) Non-Current Investments	-	-
(d) Deferred Tax Assets (Net)	-	-
(e) Long Term Loans & Advances	-	-
(f) Other Non-Current Assets	-	-
Sub-Total - Non Current Assets	-	-
2 Current Assets		
(a) Current Investments	-	-
(b) Inventories	0.44	0.44
(c) Trade Receivables	149.47	144.38
(d) Cash & Cash Equivalents	5.76	5.76
(e) Short Term Loans & Advances	4.27	4.27
(f) Other Current Assets	-	-
Sub-Total - Current Assets	159.94	154.85
TOTAL - ASSETS	159.94	154.85

